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DObjectives: To assess variation in outcome measures and their associations with shunt thrombosis prophylaxis
regimens after systemic-to-pulmonary artery shunt surgery across centers in the United States participating in
the Pediatric Health Information System database.
Methods: We reviewed data on neonates who underwent an off-pump shunt procedure at 39 centers between
2000 and 2011. The overall variation in rates of discharge mortality and shunt-related complications were
assessed by funnel plots. Complications were defined as revision/repeat of the shunt procedure during the
same admission, institution of extracorporeal membrane oxygenation after surgery, and catheter interventions
after shunt surgery. Bayesian hierarchical modeling was used to identify outliers. Shunt thrombosis prophylaxis
regimens including the time of initiation of aspirin were compared between high and low outliers.
Results: A total of 2058 index operations were identified. Funnel plots highlighting the outcomes from various
centers allowed discrimination of discharge mortality and complication rates around an aggregate of 6.7% and
12.3%, respectively. Bayesian modeling showed the presence of substantial variation in complication rates
between centers; 20% of them were identified as outliers. Aspirin was initiated significantly earlier during
the hospital course in centers with a lower composite rate of complications than those with higher rates (median
initiation day of 2 [interquartile range (IQR), 1-3] in low outliers vs 4 [IQR, 3-6] in high outliers; P<.001).
Conclusions: A substantial variation was found between hospitals in the rate of shunt-related complications.
Centers with best outcomes implement aspirin earlier in their postoperative shunt thrombosis prophylaxis
regimen. (J Thorac Cardiovasc Surg 2014;147:869-73)Supplemental material is available online.
Defining the variation in outcome measures is a
well-established method for measuring the quality of care
in pediatric cardiac surgery. Detecting variability in
outcome measures provides a clue for conducting quality
improvement initiatives that aim to optimize the best prac-
tices for the selected population.1 Systemic-to-pulmonary
artery shunt surgery, mainly the Blalock-Taussig shunt,
could be a suitable target for quality assessment efforts.
The Blalock-Taussig shunt is the first-line palliative surgery
for infants with duct-dependent pulmonary circulation.2
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The Journal of Thoracic and Cathe procedure is relatively high.3,4 This rate has been
found to be even higher in neonates, particularly those
with low birth weight.2,5,6 The reported rate of shunt-
related complications is significantly high in this age group.5
Variation in shunt thrombosis prophylaxis approaches
after systemic-to-pulmonary artery shunt surgery, which
in part represents variation of care, has been reported to
affect the rate of adverse events after shunt surgery.7,8 No
study has previously assessed variation of care after
systemic-to-pulmonary artery shunting among US pediatric
centers. There are also no published data on the best
in-hospital shunt thrombosis prophylaxis approach after
institution of systemic-to-pulmonary artery shunts.
In this article, we document the aggregate rate of adverse
events for neonatal systemic-to-pulmonary artery shunt
procedures for hospitals participating in the Pediatric Health
Information System (PHIS) database. PHIS is a large
administrative database provided by Child Health Corpora-
tion of America that contains comprehensive financial and
clinical data of the pediatric population from 43 partici-
pating hospitals. It has been widely used for comparative
effectiveness and quality improvement research studies.9
The specific goal of this study was to assess between-
participant variation in the rate of shunt mortality,
shunt-related complications, and the postoperative length
of stay (PLOS). In-hospital shunt thrombosis prophylaxisrdiovascular Surgery c Volume 147, Number 3 869
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
ICD-9 ¼ International Classification of Diseases,
ninth revision
IQR ¼ interquartile range
PDA ¼ patent ductus arteriosus
PHIS ¼ Pediatric Health Information System
PLOS ¼ postoperative length of stay
STS ¼ Society of Thoracic Surgeons
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outlier centers with regard to specific outcome measures.
METHODS
Study Cohort
Patients aged 30 days or less at the time of admission who underwent
isolated systemic-to-pulmonary artery shunt placement (International
Classification of Diseases, ninth revision [ICD-9] code 39.0, Risk Adjusted
Classification for Congenital Heart Surgery score 3)10 as the first index
operation during that admission (between January 1, 2000 and December
31, 2011) were included in the study. The study was limited to those
who had no other accompanying cardiac procedure(s) except patent ductus
arteriosus (PDA) ligation at the time of surgery (Table E1). Only hospitals
with complete discharge mortality, complication status, and PLOS data for
the calendar year were included.
As described previously,2,5 to further enhance data quality, the data were
screened to exclude patients with a diagnosis of hypoplastic left heart
syndrome. We also limited the study to systemic-to-pulmonary artery
shunts performed without cardiopulmonary bypass support.
Outcome Variables
Outcomes studied included in-hospital mortality and the occurrence of
shunt-related complications as a composite measure. This composite
measure included revision/repeat, subsequent systemic-to-pulmonary
artery shunting procedure during the same admission (ie, repeat ICD-9
code 39.0 in isolated fashion as described previously), the institution of
extracorporeal membrane oxygenation (ECMO), and catheter interven-
tions or evaluations after shunt surgery. The PLOS was also analyzed
separately. Aggregate, median, and between-participant interquartile
(25th and 75th percentiles) range for the outcome measures as well as
PLOS were calculated and summarized as raw data.
Funnel Plots
Unadjusted mortality and complication rates were plotted against the
number of subjects in each center with lines depicting exact 95% binomial
prediction limits.11
Feasibility Analysis
Following the method of Dimick and colleagues,12 we determined the
minimum number of cases each hospital had to have in order to have
50% power to detect a 2-fold increase in the outcomes compared with
the aggregate rates. Hospitals that did not meet the minimum volume
expectations for an outcome were excluded from the analyses.
Between-Participant Variation
Bayesian hierarchical modeling was used to identify outliers for
mortality, a composite measure of complication rates, as well as
PLOS. The method of estimating the adjusted hospital-level mortality,870 The Journal of Thoracic and Cardiovascular Surgcomplication rates, and average PLOS has been described
previously.13,14 We provide the unadjusted and adjusted posterior means
and 95% probability intervals for each hospital as the expected
outcomes for each hospital if they had seen patients with similar average
risk as the overall population. Adjustments were made using sex, age at
surgery, birth weight, race, noncardiac abnormalities, preoperative
diagnostic categories (single ventricle, double ventricle, and pulmonary
atresia with intact ventricular septum), and PDA ligation. For PLOS,
however, we also controlled for the occurrence of complications and
mortality during hospitalization to eliminate the effect of these 2 factors
on PLOS. To quantify overall between-participant variation, the Gini index
was calculated for outcome measures and PLOS.
In this article, the terms low outliers and high outliers are used for
centers with an average probability of mortality or complication rates lower
than the 10th and higher than the 90th percentile of outcome distribution,
respectively.
All analyses were performed using SAS 9.3 (SAS Institute, Inc, Cary,
NC). The protocol was reviewed by the Institutional Review Board of
Washington University School of Medicine, Saint Louis, Mo, and was
determined to be exempt.
Comparison of Shunt Thrombosis Prophylaxis
Regimens Between High and Low Outlier Centers
Shunt thrombosis prophylaxis regimenswere compared between high and
low outlier centers. Data from hospitals with missing medication data were
excluded from the analysis of shunt thrombosis prophylaxis regimens. Rates
of postoperative aspirin and heparin administration, and the day of start of
aspirin after surgery were compared between high and low outliers using
c2 statistics. For the purpose of comparing the shunt thrombosis prophylaxis
regimens, and to limit potential confounding of anticoagulation and aspirin
administration for reasons other than the shunt procedure, subjects with a
diagnosis of deep vein thrombosis or the need for ECMO before surgery
were excluded. For patients who experienced a complication during hospital
stay, the administration of anticoagulants and aspirin was calculated until the
day of the complication; the rationale for that was to avoid including antico-
agulant and aspirin usage for the purpose of treatment of a complication
rather than for the shunt procedure itself. We also excluded those patients
(n¼ 7, among outlier centers) who had contraindications for anticoagulation
and aspirin including gastrointestinal bleeding/peptic ulcer disease and any
diagnosis of thrombocytopenia.
RESULTS
The study included 39 centers (those with complete data)
and a total of 2058 index operations during the study
period. Table 1 provides a summary of the raw data for
the outcomes and PLOS. It includes aggregate, median,
between-participant and interquartile (25th and 75th
percentiles) range of different outcomes, including
mortality, the composite measure of complication (see
also Table E2), as well as PLOS. Table E3 summarizes pre-
operative diagnostic categories.
Funnel Plots
Funnel plots highlighting the outcomes from various
centers allowed the discrimination of the discharge
mortality rate around an aggregate of 6.7% and a
cumulative complication rate of 12.3% (Figure 1). Based
on the unadjusted funnel plots, there are several outliers,
particularly for the complication rate. Outliers made up
43.6% of the centers (30.8% as high and 12.8% as low)ery c March 2014
TABLE 1. Raw data summary
Variable Shunt placement
Number of participants 39
Number of shunt placements* 2058
Median [IQR] sample size 47 [27-73]
Range of sample size 4-157
Mortality (%)
Aggregate 6.7
Median [IQR] 6.7 [3.6-9.1]
Range 0-29.2
Complications (%)
Aggregate 12.3
Median [IQR] 10.0 [4.5-18.6]
Range 0-55.6
PLOS (days)y
Aggregate 19.7
Median [IQR] 12 [10-17]
Range 1-322
IQR, Interquartile range; PLOS, postoperative length of stay. *Not including shunt
revisions. yAfter excluding mortalities in the first week: aggregate ¼ 19.9; median
[IQR] ¼ 12 [10-17]; and range ¼ 4-322.
Heidari-Bateni et al Congenital Heart Disease
C
H
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mortality, outlier centers consisted of 17.9% (including
15.4% as high and 2.5% as low) of all participants.Bayesian Estimation of Between-Participant
Variation
Before running Bayesian models, the feasibility of
performing them was assessed. The results of the feasibility
analyses are summarized in Table 2. Based on Table 2, less
than 50% of the participating hospitals fulfilled the required
sample size to be considered in Bayesian modeling for the
mortality rate. Based on this modeling, shown in Table 3,
there were no outliers for the morality rate; however,
20% of the centers (6/30) were found to be an outlier for
complication rates after applying the feasibility require-
ment. The rate of being an outlying center for PLOS was
28.9% (11 of 38). The Gini index (Table 3) showed theFIGURE 1. Funnel plots of unadjusted in-hospital mortality and complication r
line corresponds to aggregate mortality or composite complication rates before
corresponds to an individual hospital. A, Complication data; B, mortality data.
The Journal of Thoracic and Capresence of a substantial variation in the rate of complica-
tions between centers (Gini index ¼ 0.29). With regard to
PLOS, however, the index value was 0.11, which
corresponds to a less significant variability between
participants.
Shunt Thrombosis Prophylaxis
Applying Bayesian models, 6 outliers were found for the
complication rate; 1 of them was excluded because of
insufficient data for medications and therefore, data from
5 centers (3 low and 2 high outliers) were included in the
analysis. The total number of shunt placements was 343
including 196 shunt placements in high and 147 in low out-
liers (Table E4).
The difference in the rate of aspirin administration after
surgery was not statistically significant between the groups
(78.9% in low vs 70.4% in high outliers; P ¼ .075), how-
ever, aspirin was started earlier in low outlying centers. The
median number of days heparin was used in the low outlier
group was the same as the high outlier group (2 days [inter-
quartile range (IQR), 1-5] vs 3 days [IQR, 1-4]; P ¼ .50).
Figure 2 illustrates the distribution of the initiation of
aspirin between the 2 groups. The median day of initiation
of aspirin in low outliers was lower than the median day in
high outliers (2 days [IQR, 1-3] vs 4 days [IQR, 3-6];
P<.001).
DISCUSSION
This study depicts and quantifies variation in outcome
measures among centers after the institution of systemic-
to-pulmonary artery shunts in neonates. Furthermore,
outlying centers are detected by means of Bayesian
hierarchical modeling, and thrombosis prophylaxis regi-
mens are compared between high and low outlying centers.
Between-hospital variation was found predominantly in
complication rates. More than 40% of centers were found
to be outside the binomial prediction limits in the funnel
plot for complication rate. However, about 15% ofates after the systemic-to-pulmonary artery shunt procedure. The horizontal
discharge; curved lines depict 95% binomial prediction limits. Each circle
BTS, Blalock-Taussig shunt.
rdiovascular Surgery c Volume 147, Number 3 871
TABLE 2. Feasibility of analyzing between-center variation
Variable Shunt placement
Number of hospitals 39
Complications
Aggregated complication rate (%) 12.3
Sample size required for 50% power to detect
23 increase in complication
26
Number of hospitals meeting complication
requirement
30
Mortality
Aggregated mortality rate (%) 6.7
Sample size required for 50% power to detect
23 increase in mortality
50
Number of hospitals meeting mortality
requirement
19
PLOS
Number of hospitals meeting PLOS
requirement (5 cases)
38
PLOS, Postoperative length of stay.
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Dparticipating centers were outliers for the mortality rate. In a
funnel plot, it is expected that a maximum of 5% of
participants will be randomly outside the 95% limits
around the aggregate rate. The finding that more than
40% of the participants fell outside the prediction limits
for the complication rate, suggest nonrandom variation in
the rate of complications, which is in part representative
of variation of care between centers.
Bayesian estimation modeling was used to detect
outlying centers for mortality and complication rates, and
for PLOS. We defined the estimated values for the
10th and 90th percentiles of risk-adjusted mortality or
complication rates as the cut-off points for detecting the
outliers. The same cut-off points were used previously to
describe an index to quantify variation in discharge
mortality rates for pediatric cardiac surgical operations
between hospitals in 2 studies done by Jacobs and
colleagues.13,14 They did not, however, compare the
outlier centers to detect possible reasons for the variability.TABLE 3. Results of Bayesian hierarchical models: estimated percentiles
including the number of low and high outliers in each model
Estimate (95% B
Minimum 25th percentile 50th percentile 75th
Hospital-specific complication rates
Unadjusted 5.5 (1.9-10.9) 7.3 (2.3-15) 9.3 (3.4-17.9) 15.1
Adjusted 4 (1.1-8.7) 6.5 (2.7-11.9) 8.8 (3.7-16.1) 13.3
Hospital-specific mortality rates
Unadjusted 5.5 (3-7.9) 6 (3.5-8.7) 6.6 (4-9.9) 6.8
Adjusted 3.7 (1.7-6.5) 4.3 (2.2-7.1) 4.8 (2.3-8.4) 6.5
Hospital-specific PLOS
Unadjusted 9.5 (7.3-12.2) 11.4 (9.5-13.7) 13.1 (10.5-16.3) 15.5
Adjusted 9.4 (7.4-12.3) 11.6 (10.3-13.1) 13.8 (11.3-16.8) 14.6
PLOS, Postoperative length of stay.
872 The Journal of Thoracic and Cardiovascular SurgAlthough the funnel plot and Gini index both disclosed
variations in mortality rates, no outliers were found in the
Bayesian modeling. One reason for this finding might be
the robust cut-off points chosen to define outliers.
Furthermore, there was about 50% attrition for the total
number of participating hospitals after applying the
feasibility requirement in Bayesian modeling.
With regard to PLOS, however, the variability was
quantified to be less than other outcome measures. For
PLOS, the occurrence of a complication or mortality was
considered as an adjustor in the Bayesian hierarchical
modeling. This means that PLOS variation, as described
here, is unrelated to the occurrence of adverse events in
participating hospitals.
We looked for possible distinguishing features between
outliers related to pattern of use of anticoagulants and
particularly aspirin after surgery. Anticoagulation and
antiplatelet regimens after shunt placement have been
reported as factors affecting the outcome.7,8 Our results
revealed that centers with a lower composite rate of
complications started aspirin much sooner during the
hospital course (Figures 2 and E1). Aspirin has been
reported to be effective in lowering mortality after
discharge7,15; our findings suggest that the same practice
pattern leads to improved in-hospital outcomes.
Our study has some limitations. There is often concern
related to the use of administrative data and coding
inaccuracies; we have done our best to use inclusion and
exclusion criteria, as described previously, to define a
population that has yielded results matching our own
institutional clinical data as well as aggregate data from
the Society of Thoracic Surgeons (STS) congenital
database. It has been shown that patient records in the
PHIS database are highly matched to the STS database.16
We have also validated our results by crosschecking the
data with the clinical data in our own institute. We found
high concordance between the PHIS data and our
institutional clinical dataset.of distribution of mortality, and complication rates and average PLOS
ayesian probability interval)
percentile Maximum Gini index
Number of outliers
Low High
(7-26) 23.6 (13.4-36.3) 0.24 2 1
(6.9-22.1) 25.7 (16.6-37.2) 0.29 4 2
(4.3-10.4) 7.9 (5.1-13.1) 0.05 0 0
(3-12.4) 9.9 (4.5-18.9) 0.18 0 0
(11.2-21.7) 21 (17-26.1) 0.12 0 10
(11.9-17.7) 21.6 (18-25.8) 0.11 4 7
ery c March 2014
FIGURE 2. Distribution of start day of aspirin in patients in outlier centers. A, Aspirin start day in low outlying centers. B, Aspirin start day in high outlying
centers in off-pump cohort.
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ables, and only considered institution-specific experience/
volume. Variation in a surgeon’s performance could be a po-
tential reason for variation in mortality rates among centers,
although we would expect those to be reflected more in
early/immediate mortalities or complications.
There have also been concerns about using and reporting
composite end points in clinical studies,17 which might be
misleading. We tried to address this issue by logically
constructing the composites, using expert opinions, and
performing a literature review before pulling the data. We
have also presented data for all the components of the
composite complication in supplemental files (Tables E2
and E5). We considered any catheter-based procedure after
shunt placement during the hospital stay as a potential
complication after the shunting. However, there is always a
possibility that the catheter-based procedure was done for
reasons other than detecting or addressing shunt problems.
As another limitation in our study, we could not differentiate
mortalities unrelated to shunt occlusions. We limited our
analysis to heparin and aspirin as the database contains
limited information on alternative thrombosis prophylaxis
regimens such as clopidogrel (Plavix) or enoxaparin (Love-
nox). These alternative medical regimens may be important
although recent published literature on clopidogrel does not
suggest incremental benefit from that drug over aspirin use.18
In conclusion, a substantial variation was found between
hospitals in the rate of shunt-related complications.Our result
can be an incentive to conduct quality improvement initia-
tives to improve the quality of care for patients undergoing
systemic-to-pulmonary artery shunting. We found that early
aspirin use is more commonly seen in centers with better out-
comes. Thismight suggest that, in systemic-to-pulmonary ar-
tery shunts performed off-pump, earlier initiation of aspirin
therapy results in better outcomes.References
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FIGURE E1. Comparison of start day of aspirin between patients from centers with high, low, and average complication rates.
Congenital Heart Disease Heidari-Bateni et al
873.e1 The Journal of Thoracic and Cardiovascular Surgery c March 2014
C
H
D
TABLE E1. ICD-9 codes for cardiac surgical procedures
ICD-9 code Procedure
35.01 Closed heart valvotomy, aortic valve
35.02 Closed heart valvotomy, mitral valve
35.04 Closed heart valvotomy, tricuspid valve
35.10 Open heart valvuloplasty without replacement
35.11 Open heart valvuloplasty of aortic valve without replacement
35.12 Open heart valvuloplasty of mitral valve without replacement
35.13 Open heart valvuloplasty of pulmonary valve without
replacement
35.14 Open heart valvuloplasty of tricuspid valve without
replacement
35.20 Open and other replacement of unspecified heart valve
35.21 Open and other replacement of aortic valve with tissue graft
35.22 Open and other replacement of aortic valve
35.23 Open and other replacement of mitral valve with tissue graft
35.24 Open and other replacement of mitral valve
35.27 Open and other replacement of tricuspid valve with tissue
graft
35.28 Open and other replacement of tricuspid valve
35.31 Operations on papillary muscle
35.32 Operations on chordae tendineae
35.33 Annuloplasty
35.34 Infundibulectomy
35.35 Operations on trabeculae carneae cordis
35.50 Repair of unspecified septal defect of heart with prosthesis
35.51 Repair of atrial septal defect with prosthesis
35.52 Repair of atrial septal defect with prosthesis, closed
technique
35.53 Repair of ventricular septal defect with prosthesis, open
technique
35.54 Repair of endocardial cushion defect with prosthesis
35.70 Other and unspecified repair of unspecified septal defect
of heart
35.71 Other and unspecified repair of atrial septal defect
35.72 Other and unspecified repair of ventricular septal defect
35.73 Other and unspecified repair of endocardial cushion defect
35.81 Total repair of tetralogy of Fallot
35.82 Total repair of total anomalous pulmonary venous connection
35.83 Total repair of truncus arteriosus
35.84 Total correction of transposition of great vessels
35.91 Interatrial transposition of venous return
35.92 Creation of conduit between right ventricle and pulmonary
artery
35.93 Creation of conduit between left ventricle and aorta
37.50 Heart replacement procedures
37.51 Heart transplantation
37.52 Implantation of total internal biventricular heart replacement
system artificial heart
39.21 Caval-pulmonary artery anastomosis
ICD-9, International Classification of Diseases, ninth revision.
TABLEE2. Rates of catheter intervention, shunt revision, and ECMO
in the studied population
Variable Shunt placement
Catheter intervention (%)
Aggregate 7.7
Median [IQR] 6.3 [3.1-12.5]
Range 0-55.6
Shunt revision (%)
Aggregate 3.5
Median [IQR] 1.4 [0-4.2]
Range 0-27.3
ECMO (%)
Aggregate 2.9
Median [IQR] 1.3 [0-4.1]
Range 0-19.1
ECMO, Extracorporeal membrane oxygenation; IQR, interquartile range.
TABLE E3. Preoperative diagnostic categories and frequency of
additional source of blood flow in the studied population
Diagnostic category Number of cases (%)
Single ventricle 427 (20.7)
Double ventricles 1304 (63.4)
Pulmonary atresia with intact ventricular septum 327 (15.9)
Additional source of pulmonary flow 1244 (60.4)
Posterior descending artery not ligated 596 (29)
Heidari-Bateni et al Congenital Heart Disease
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TABLE E4. Comparison of baseline characteristics between patients
from high and low outlier centers
Variable
Number of cases (%)
P
value
High outliers
(n ¼ 196)
Low outliers
(n ¼ 147)
Diagnostic categories .840
Single ventricle 44 (22.4) 34 (23.1)
Double ventricles 118 (60.2) 91 (61.9)
Pulmonary atresia with
intact ventricular septum
34 (17.3) 22 (15.0)
Additional source of
pulmonary flow
124 (58.8) 87 (54.5) .442
Posterior descending artery
not ligated
47 (24.0) 46 (31.3) .132
Birth weight (g  SD) 2822  614 2948  586 .112
Age at surgery (d  SD) 10  22 9  8 .586
Male gender 110 (56.1) 87 (59.2) .570
Noncardiac anomalies 130 (66.3) 106 (72.1) .253
Aspirin received on day of
surgery
3 (1.5) 24 (16.3) <.001
SD, Standard deviation.
TABLE E5. Distribution of factors of composite complications in
patients from high and low outlier centers
Variable
Shunt placement (%)
High outliers (n ¼ 196) Low outliers (n ¼ 147)
Catheter intervention
Aggregate 9.7 1.4
Median [IQR] 9.5 [-] 0 [0-3.2]
Range 9.1-9.9 0-3.2
Shunt revision
Aggregate 6.1 0.7
Median [IQR] 10.4 [-] 0 [0-1.9]
Range 2.6-18.2 0-1.9
ECMO
Aggregate 6.1 0
Median [IQR] 5.5 [-] 0 [0-0]
Range 4.5-6.6 —
IQR, Interquartile range; ECMO, extracorporeal membrane oxygenation.
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